<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">The anti-inflammatory activity of 
 <italic>T. albicans</italic> main compounds is broadly reported in both pre-clinical and clinical studies. Accordingly, in a clinical study conducted by Juergens et al.
 <sup>
  <xref ref-type="bibr" rid="CR52">52</xref>
 </sup>, 1,8-cineole revealed anti-inflammatory activity in patients with severe asthma. Using human cell lines, Greiner et al.
 <sup>
  <xref ref-type="bibr" rid="CR53">53</xref>
 </sup> demonstrated the ability of 1,8-cineole to attenuate the activity of NF-κB, thus decreasing its nuclear translocation and consequently reducing the expression of its target genes coding for pro-inflammatory mediators. Nogueira et al.
 <sup>
  <xref ref-type="bibr" rid="CR54">54</xref>
 </sup> showed that it modulates the production of pro-inflammatory cytokines by LPS-stimulated macrophages by interfering with NF-κB, p38 or ERK/MAPK pathways. Peana et al.
 <sup>
  <xref ref-type="bibr" rid="CR55">55</xref>
 </sup> demonstrated the capacity of linalool to reduce NO production in LPS-stimulated macrophages, although it failed to inhibit iNOS expression. The authors suggested that linalool could possibly act as a scavenger of NO or as an inhibitor of iNOS activity.
</p>
